[go: up one dir, main page]

AR057295A1 - Combinaciones y procedimientos para usar un compuestos de indolinona - Google Patents

Combinaciones y procedimientos para usar un compuestos de indolinona

Info

Publication number
AR057295A1
AR057295A1 ARP060101895A ARP060101895A AR057295A1 AR 057295 A1 AR057295 A1 AR 057295A1 AR P060101895 A ARP060101895 A AR P060101895A AR P060101895 A ARP060101895 A AR P060101895A AR 057295 A1 AR057295 A1 AR 057295A1
Authority
AR
Argentina
Prior art keywords
indolinona
procedures
combinations
compounds
compound
Prior art date
Application number
ARP060101895A
Other languages
English (en)
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of AR057295A1 publication Critical patent/AR057295A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Procedimientos para el tratamiento de cáncer usando un compuesto de formula (1) o una sal farmacéuticamente aceptable de mismo, particularmente una sal malato, sola o en combinacion con diversos agentes terapéuticos adicionales. La presente también proporciona terapias de combinacion para el tratamiento del cáncer, y regímenes de dosificacion terapéuticos, usando el compuesto de formula (1).
ARP060101895A 2005-05-12 2006-05-11 Combinaciones y procedimientos para usar un compuestos de indolinona AR057295A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US68083705P 2005-05-12 2005-05-12
US75379705P 2005-12-23 2005-12-23

Publications (1)

Publication Number Publication Date
AR057295A1 true AR057295A1 (es) 2007-11-28

Family

ID=36809412

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101895A AR057295A1 (es) 2005-05-12 2006-05-11 Combinaciones y procedimientos para usar un compuestos de indolinona

Country Status (13)

Country Link
US (1) US20080193448A1 (es)
EP (1) EP1885355A1 (es)
JP (1) JP2006316060A (es)
KR (1) KR20070119745A (es)
AR (1) AR057295A1 (es)
AU (1) AU2006245421A1 (es)
BR (1) BRPI0609957A2 (es)
CA (1) CA2603445A1 (es)
IL (1) IL186230A0 (es)
MX (1) MX2007014087A (es)
RU (1) RU2007141654A (es)
TW (1) TW200722083A (es)
WO (1) WO2006120557A1 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113952338A (zh) 2005-02-03 2022-01-21 综合医院公司 治疗吉非替尼耐药性癌症的方法
CN103110948A (zh) 2005-11-04 2013-05-22 惠氏公司 mTOR抑制剂、赫赛汀和/或HKI-272的抗肿瘤组合
WO2007056117A1 (en) * 2005-11-04 2007-05-18 Wyeth Antineoplastic combinations of temsirolimus and sunitinib malate
JPWO2008075741A1 (ja) * 2006-12-20 2010-04-15 国立大学法人 長崎大学 糖尿病治療剤及び予防剤
US20100087499A1 (en) * 2007-01-30 2010-04-08 Schering Corporation Pharmaceutical compositions and methods of using temozolomide and multi-targeted kinase inhibitors
CN101646458A (zh) * 2007-02-01 2010-02-10 健泰科生物技术公司 使用血管发生抑制剂的联合疗法
KR20090115866A (ko) 2007-03-05 2009-11-09 교와 핫꼬 기린 가부시키가이샤 의약 조성물
EP2182984A2 (en) * 2007-08-02 2010-05-12 Nerviano Medical Sciences S.r.l. A morpholinyl anthracycline derivative combined with protein kinase inhibitors
US8022216B2 (en) 2007-10-17 2011-09-20 Wyeth Llc Maleate salts of (E)-N-{4-[3-chloro-4-(2-pyridinylmethoxy)anilino]-3-cyano-7-ethoxy-6-quinolinyl}-4-(dimethylamino)-2-butenamide and crystalline forms thereof
CA2699305A1 (en) * 2007-11-21 2009-05-28 Teva Pharmaceutical Industries Ltd. Polymorphs of sunitinib base and processes for preparation thereof
EP3135285B1 (en) 2008-06-17 2018-08-15 Wyeth LLC Antineoplastic combinations containing hki-272 and vinorelbine
CA2731605A1 (en) 2008-07-24 2010-01-28 Teva Pharmaceutical Industries Ltd. Sunitinib and salts thereof and their polymorphs
CN105963313A (zh) * 2008-08-04 2016-09-28 惠氏有限责任公司 4-苯胺基-3-氰基喹啉和卡培他滨的抗肿瘤组合
US8129396B2 (en) * 2008-09-29 2012-03-06 Telik, Inc. 2-[1H-benzimidazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides and 2-[benzothiazol-2(3H)-ylidene]-2-(pyrimidin-2-yl)acetamides as kinase inhibitors
KR20190128004A (ko) 2009-04-06 2019-11-13 와이어쓰 엘엘씨 네라티닙을 이용한 유방암의 치료법
EA201290400A1 (ru) * 2009-11-30 2013-01-30 Протеолоджикс, Лтд. Малые производные пиримидина и способы их использования
WO2012042421A1 (en) 2010-09-29 2012-04-05 Pfizer Inc. Method of treating abnormal cell growth
US20120114638A1 (en) * 2010-11-08 2012-05-10 John Boylan Combination therapy
RU2659936C2 (ru) * 2012-03-06 2018-07-04 Зэ Борд оф Трастиз оф зэ Юниверсити оф Иллинойс Активация прокаспазы-3 с помощью комбинированной терапии
WO2013152193A2 (en) * 2012-04-04 2013-10-10 Beth Israel Deaconess Medical Center, Inc. Methods of treating proliferative disorders with malate or derivatives thereof
CN105457021A (zh) 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
JP2017512748A (ja) * 2012-06-25 2017-05-25 バイエル・ヘルスケア・エルエルシーＢａｙｅｒ ＨｅａｌｔｈＣａｒｅ ＬＬＣ スニチニブを含んでいる眼科用局所医薬組成物
KR101532999B1 (ko) * 2014-02-19 2015-07-02 서울대학교병원 (분사무소) 수니티닙 내성을 가진 신장암 세포주
EP3169374B1 (en) 2014-07-14 2022-01-05 University of Utah Research Foundation In situ solidifying complex coacervates and methods of making and using thereof
CA2973857C (en) 2015-01-16 2023-11-07 Chugai Seiyaku Kabushiki Kaisha Combination drug
WO2019084548A1 (en) * 2017-10-27 2019-05-02 University Of Utah Research Foundation COMPLEX LIQUID IN SITU SOLIDIFICATION COASTALITIES FOR LOCAL ADMINISTRATION OF ANTI-ANGIOGENIC AGENTS OR CHEMOTHERAPEUTIC AGENTS
US11896234B2 (en) 2018-01-26 2024-02-13 Fluidx Medical Technology, Llc Apparatus and method of using in situ solidifying complex coacervates for vascular occlusion
WO2022216184A1 (en) * 2021-04-08 2022-10-13 Joint Stock Company "Biocad" Malignant neoplasis treatment using pd-1 antibody combination

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY130363A (en) * 2000-02-15 2007-06-29 Sugen Inc "pyrrole substituted 2-indolinone protein kinase inhibitors"
US6484567B1 (en) * 2000-08-03 2002-11-26 Symyx Technologies, Inc. Rheometer for rapidly measuring small quantity samples
AR038957A1 (es) * 2001-08-15 2005-02-02 Pharmacia Corp Terapia de combinacion para el tratamiento del cancer
CA2455050C (en) * 2001-08-15 2007-02-20 Pharmacia & Upjohn Company Crystals including a malic acid salt of n-[2-(diethylamino) ethyl]-5-[(5-fluoro-2-oxo-3h-indole-3-ylidene) methyl]-2, 4-dimethyl-1h-pyrrole-3-carboxamide, processes for its preparation and compositions thereof
TWI259081B (en) * 2001-10-26 2006-08-01 Sugen Inc Treatment of acute myeloid leukemia with indolinone compounds
AR042042A1 (es) * 2002-11-15 2005-06-08 Sugen Inc Administracion combinada de una indolinona con un agente quimioterapeutico para trastornos de proliferacion celular
US20040209937A1 (en) * 2003-02-24 2004-10-21 Sugen, Inc. Treatment of excessive osteolysis with indolinone compounds
WO2005023765A1 (en) * 2003-09-11 2005-03-17 Pharmacia & Upjohn Company Llc Method for catalyzing amidation reactions by the presence of co2
US20050182122A1 (en) * 2003-11-20 2005-08-18 Bello Carlo L. Method of treating abnormal cell growth using indolinone compounds

Also Published As

Publication number Publication date
JP2006316060A (ja) 2006-11-24
RU2007141654A (ru) 2009-05-20
CA2603445A1 (en) 2006-11-16
BRPI0609957A2 (pt) 2010-05-11
WO2006120557A1 (en) 2006-11-16
TW200722083A (en) 2007-06-16
IL186230A0 (en) 2008-01-20
AU2006245421A1 (en) 2006-11-16
KR20070119745A (ko) 2007-12-20
US20080193448A1 (en) 2008-08-14
EP1885355A1 (en) 2008-02-13
MX2007014087A (es) 2008-02-07

Similar Documents

Publication Publication Date Title
AR057295A1 (es) Combinaciones y procedimientos para usar un compuestos de indolinona
EA200970932A1 (ru) Способы лечения с применением пиридопиримидиноновых ингибиторов pi3k альфа
PT2139483E (pt) Terapias de combinação que compreendem um inibidor de quinoxalina de pi3k-alfa para utilizar no tratamento de cancro
ECSP099436A (es) Acilaminopirazoles como inhibidores de fgfr
CR11510A (es) Uso de un inhibidor de la gamma-secretasa para tratamiento del cancer
AR059948A1 (es) Formas farmaceuticas y metodos de tratamiento que usan un inhibidor de la tirosinacinasa
AR051099A1 (es) Combinaciones terapeuticas que comprenden inhibidor de poli(adp-ribosa)polimerasas
EA201391286A1 (ru) Лечение солидных опухолей
WO2009156735A3 (en) New therapeutic agents
GT200900283A (es) "terapia de combinación con un compuesto actuando como un inhibidor del receptor adp plaquetario".
AR090349A1 (es) Terapia de combinacion para trastornos proliferativos, kit y uso
CR20140086A (es) Tratamientos de combinación para hepatitis c
CL2011000916A1 (es) Uso de una combinacion de un inhibidor de proteasoma epoxicetona peptidica o una sal farmaceutica aceptable del mismo, y uno o mas de otros agentes terapeuticos para tratar el cancer.
AR060089A1 (es) Tratamiento del dolor
MX2019009227A (es) Métodos para tratar cáncer con inhibidores de hsp90.
MX2018012165A (es) Metodos de tratamiento de canceres pediatricos.
ATE543492T1 (de) Behandlung von lungenkrebs
UY30158A1 (es) Uso de derivados de benzo-heteroaril sulfamida para el tratamiento del dolor
MX2009005798A (es) Recuperacion de apoplejia.
AR062248A1 (es) Composiciones y metodos para tratar artritis reumatoidea
EA200702026A1 (ru) Лечение или предупреждение зуда
GB0606015D0 (en) therapeutic agents
AR069008A1 (es) Composicion farmaceutica para tratar un linfoma en un perro que comprende idarubicina, uso
CO6150148A2 (es) Un inhibidor aminoisoquinolina trombina con biodisponibilidad mejorada
DOP2009000241A (es) Inhibidores de quinaxolina de pi3k-alfa para el tratamiento del cancer

Legal Events

Date Code Title Description
FA Abandonment or withdrawal